The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | Updates from a Phase II study evaluating zanubrutinib, ixazomib and dexamethasone in WM
Shuhua Yi, MD, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China, discusses the main aims and findings of a Phase II study evaluating the combination of zanubrutinib, ixazomib and dexamethasone for the treatment of patients with Waldenström’s macroglobulinemia (WM). Dr Yi first explains the rationale behind this trial, and then highlights the main results, as well as the need for more research in this space. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
